Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.
暂无分享,去创建一个
S. Lallechère | K. Astruc | S. Aho | L. Piroth | C. Neuwirth | P. Chavanet | P. Cassier
[1] A. Oliver,et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Y. Carmeli,et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] K. Prasad,et al. Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. , 2009, The Indian journal of medical research.
[4] J. Blázquez,et al. Effect of Subinhibitory Concentrations of Antibiotics on Intrachromosomal Homologous Recombination in Escherichia coli , 2009, Antimicrobial Agents and Chemotherapy.
[5] F. Ariey,et al. CTX-M β-Lactamases in Escherichia coli from Community-acquired Urinary Tract Infections, Cambodia , 2009, Emerging infectious diseases.
[6] M. Mulvey,et al. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. , 2009, Diagnostic microbiology and infectious disease.
[7] F. Baquero,et al. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[8] Kevin B Laupland,et al. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. , 2008, International journal of antimicrobial agents.
[9] K. Laupland,et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern , 2008 .
[10] P. J. Z. Teixeira,et al. The effect of control group selection in the analysis of risk factors for extended spectrum beta-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. , 2008, The Journal of hospital infection.
[11] A. Apisarnthanarak,et al. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. , 2007, American journal of infection control.
[12] I. Matic,et al. Antibiotic‐mediated recombination: ciprofloxacin stimulates SOS‐independent recombination of divergent sequences in Escherichia coli , 2007, Molecular microbiology.
[13] J. Lavigne,et al. CTX-M β-Lactamase-Producing Escherichia coli in French Hospitals: Prevalence, Molecular Epidemiology, and Risk Factors , 2006, Journal of Clinical Microbiology.
[14] M. Kaufmann,et al. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. , 2006, The Journal of hospital infection.
[15] Y. Chuang,et al. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[16] J. Ariza,et al. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[17] J. Rodríguez-Baño,et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Robert A. Bonomo,et al. Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .
[19] D. Church,et al. Community-Wide Outbreaks of Clonally Related CTX-M-14 β-Lactamase-Producing Escherichia coli Strains in the Calgary Health Region , 2005, Journal of Clinical Microbiology.
[20] R. Colodner. Extended-spectrum beta-lactamases: a challenge for clinical microbiologists and infection control specialists. , 2005, American journal of infection control.
[21] G. Rossolini,et al. Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. , 2005, International journal of antimicrobial agents.
[22] B. Schlemmer,et al. Outbreak of nosocomial infections due toKlebsiella pneumoniae producing SHV-4 beta-lactamase , 1990, European Journal of Clinical Microbiology and Infectious Diseases.
[23] J. Rodríguez-Baño,et al. Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.
[24] F. Pérez,et al. Outbreak of SHV-5 beta-lactamase-producing Klebsiella pneumoniae in a neonatal-pediatric intensive care unit in Spain. , 2004, Microbial drug resistance.
[25] R. Labia,et al. First isolation of CTX-M15-producing Escherichia coli from two French patients. , 2003, The Journal of antimicrobial chemotherapy.
[26] M. Lipsitch,et al. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] J. Patel,et al. Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species: Risk Factors for Colonization and Impact of Antimicrobial Formulary Interventions on Colonization Prevalence , 2002, Infection Control & Hospital Epidemiology.
[28] D. Paterson. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] L. Tzouvelekis,et al. CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes , 2000 .
[30] J. Ariza,et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. , 1997, The Journal of hospital infection.
[31] F. Goldstein,et al. Communiqué 1992 du comité de l'antibiogramme de la société française de microbiologie , 1990 .
[32] V. Jarlier,et al. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. , 1988, Reviews of infectious diseases.